Measure the live uptake of fluorescence, bacterial bioparticles by human, iPSC-derived microglia.
ASSAY USING RELEVANT, RELIABLE IN VITRO MODELS
Microglia are the immune-effector cells in the CNS that are activated in response to injury, neurodegeneration, and infection. One major function of these cells is phagocytosis of potential threats to neuronal health, including pathogens and extracellular protein aggregates. Microglia are also largely responsible for neurite-network modulation, synapse pruning, and clearing of dead cells. The implication of these varied and numerous roles of microglia are becoming clearer in neurodegenerative diseases, such as Alzheimer’s disease, in which prolonged activation of microglia leads to neuronal death. Identifying therapeutics that can modulate microglial activity remains a promising avenue for drug development, but these efforts are stymied by the unavailability of relevant, reliable in vitro models with which to screen candidates. Most studies resort to using rodent-derived or immortalized microglial models that do not mirror human biology. Some assays use primary microglia, but sufficient cells are difficult to isolate and, when isolated, are largely already activated.
USING PHYSIOLOGICALLY RELEVANT CELL MODELS IN HUMAN iPSC-DERIVED MICROGLIA
Our Ready-2-Go Microglia Phagocytosis Assay Service measures the uptake of bacterial bioparticles by a physiologically relevant cell model – human iPSC-derived microglia (Fujifilm CDI). These iPSC-microglia afford reproducible results and can be scaled up to medium- or high-throughput formats for screening compounds. To incorporate Alzheimer’s disease relevance into this assay offering, you can choose between wild-type, TREM2 homozygous, or TREM2 heterozygous cell lines.
APPLICABLE RESEARCH & DISEASE AREAS
This assay is valuable in the development of any CNS-targeting therapies or for evaluating potential neuroinflammatory, off-target effects of non-CNS-targeting therapies on neuronal health. It is highly relevant to neurodegenerative-disease research, especially Alzheimer’s disease through the option of using TREM2-mutant cell lines.
Human iPSC-derived microglia (Fujifilm CDI) are seeded into 384-well plates and left to recover before compound addition. The cells are then treated with reference compounds that promote or inhibit activation of phagocytosis along with your test articles overnight. Bacterial bioparticles that fluoresce upon cellular uptake are added to the cells, and fluorescence is measured every hour for 24 hours. Cells are then fixed and imaged on a high-content microscope, and images are analyzed to provide you quantitative, end-point assessments of your compounds’ effects on microglial phagocytosis.
RELATED READY-2-GO SERVICES
Browse related Ready-2-Go assay offerings. For custom assays, check out our Bespoke Services.
Multiplexed readouts of viability and apoptosis.
R2G NEURONAL MITOCHONDRIAL HEALTH
Multiplexed readouts of mitochondrial health.
R2G NEURITE OUTGROWTH & NEURITE NETWORK DYNAMICS
Quantification of neurite outgrowth and changes in established neurite networks using human, iPSC-derived neurons.
Let's discuss how we can help with your research.